Newsletter Subject

After Lariat LAA Ligater Disappoints in aMAZE, is a Path Ahead Still Possible?

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Tue, Apr 2, 2024 10:47 PM

Email Preheader Text

Daily Headlines Tuesday, April 02, 2024 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLIGHT

[MEDPAGE TODAY]( Daily Headlines Tuesday, April 02, 2024 Today's Top Stories for {NAME} [CARDIOLOGY]( [After Lariat LAA Ligater Disappoints in aMAZE, is a Path Ahead Still Possible?]( [PERSPECTIVES]( [A Closer Look at the New Statin Therapy Guidelines for Patients With HIV]( [SPECIAL REPORTS]( [Weight-Loss Drug Zepbound Faces Supply Issues]( THE BREAK ROOM [Spell Check-Up: Try to Pass This Spelling Quiz]( CME SPOTLIGHT [Expanding Evaluation and Referral of Anemia in Primary Care Settings to Diagnose Underlying Myelodysplastic Syndromes]( [PULMONOLOGY]( [E-Cigarettes Tied to Heart Failure]( [SPECIAL REPORTS]( [FDA Warning Letters Detail Controversy at Psychiatric Institute]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [CARDIOLOGY]( [SGLT2i Better Than Diuretic for Early Decongestion in Acute Heart Failure?]( CME SPOTLIGHT [Optimizing Anemia Management in Patients With Myelodysplastic Syndrome, Myelofibrosis, and Beta Thalassemia Through Shared Decision-Making]( [NEUROLOGY]( [Caffeine and Parkinson's; Brutally Honest Look at Dementia; Three MS Subtypes]( [RHEUMATOLOGY]( [No Response to TNF Inhibitor in JIA? Another May Do the Trick]( [CARDIOLOGY]( [FDA Approves TriClip; Fortified Eggs vs Cholesterol; Impella Maker Chided]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Supporting Patients in Navigating Novel Therapies for Multiple Myeloma Treatment]( [ENDOCRINOLOGY]( [Diabetes Drugs Overpriced; Hormone Drugs and Brain Tumors; Menopause or Herpes?]( [INFECTIOUS DISEASE]( [Flu Vaccine Uptake Tripled With Simple Promotion]( [GASTROENTEROLOGY]( [How Old Is Too Old for Surveillance Colonoscopy?]( CME SPOTLIGHT [Navigating Transitions to Adult Care for Sickle Cell Disease: A Toolkit for Healthcare Providers and Their Patients]( [WASHINGTON-WATCH]( [Defense Official Had Havana Syndrome Symptoms at NATO Summit, Pentagon Confirms]( [RADIOLOGY]( [Microwave Ablation a Safer Option for Multifocal Papillary Thyroid Carcinoma?]( [MEETING COVERAGE]( [Children Attending Daycare May Have Lower Risk of Asthma and Allergies]( CME SPOTLIGHT [Positioning CAR T-Cell Therapy in the CLL Treatment Landscape]( [PERSPECTIVES]( [The Baltimore Bridge Collapse Aftermath: Determining Causes of Death]( [ONCOLOGY/HEMATOLOGY]( [More Evidence Ties Tumor Infiltrating Lymphocytes to TNBC Outcomes]( [SPECIAL REPORTS]( [HHS Cracks Down on Care Facilities for Failure to Turn Over Medical Records]( CME SPOTLIGHT [Applying the Latest Clinical Evidence to Treatment Plans for Pediatric Patients With Hodgkin Lymphoma]( [ASCO READING ROOM]( [Metabolites and Breast Cancer Risk]( # Weekly Survey [Will the Supreme Court Reduce Abortion Pill Access?]( The Supreme Court [heard oral arguments]( in a case centered around whether the FDA overlooked safety concerns when it eliminated certain barriers to accessing the abortion pill, mifepristone (Mifeprex)[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2024-04-02&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

26/05/2024

Sent On

26/05/2024

Sent On

25/05/2024

Sent On

24/05/2024

Sent On

24/05/2024

Sent On

24/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.